Submission to the Patented Medicines Pricing Review Board - Draft Guidelines


Date de parution : 12/05/2022
Personne(s)-ressource(s) : Joan Weir

The Canadian Life and Health Insurance Association (CLHIA) is pleased to provide the views of its members to the Patented Medicines Pricing Review Board (PMPRB) for consideration regarding the draft Guidelines, which define the processes for review of drug pricing for patented drugs approved in Canada.